Junhui Wang

Quzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer.

Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer.

Journal: Annals of medicine
Published: October 15, 2025

Dose-escalated icotinib in frail, older adults patients with EGFR-mutant lung adenocarcinoma: real-world efficacy and safety in a high-risk cohort.

Dose-escalated icotinib in frail, older adults patients with EGFR-mutant lung adenocarcinoma: real-world efficacy and safety in a high-risk cohort.

Journal: Frontiers in oncology
Published: September 07, 2025

Prognostic Significance of baseline systemic inflammation markers in PD-L1-negative advanced non-small cell lung cancer patients treated with the BRICS sequential regimen.

Prognostic Significance of baseline systemic inflammation markers in PD-L1-negative advanced non-small cell lung cancer patients treated with the BRICS sequential regimen.

Journal: Frontiers in immunology
Published: August 15, 2025

Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study.

Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study.

Journal: Frontiers in immunology
Published: August 01, 2025

Preliminary study on BRICS sequential therapeutic regimen as salvage treatment for refractory advanced colorectal cancer patients harboring pMMR status.

Preliminary study on BRICS sequential therapeutic regimen as salvage treatment for refractory advanced colorectal cancer patients harboring pMMR status.

Journal: Frontiers in immunology
Published: July 22, 2025

Durable Control of Multi-Refractory HBV-HCC with Bevacizumab/Sintilimab/Lenvatinib Triplet Therapy.

Durable Control of Multi-Refractory HBV-HCC with Bevacizumab/Sintilimab/Lenvatinib Triplet Therapy.

Journal: Cancer management and research
Published: June 20, 2025

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.

Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer.

Journal: Medicine
Published: February 23, 2024

Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study.

Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study.

Journal: Scientific reports
Published: September 26, 2023

Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer.

Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer.

Journal: Immunotherapy
Published: March 23, 2023

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors.

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors.

Journal: Frontiers in pharmacology
Published: March 20, 2023

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report.

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report.

Journal: Medicine
Published: January 27, 2023

STK11 loss and SMARCB1 deficiency mutation in a dedifferentiated lung cancer patient present response to neo-adjuvant treatment with pembrolizumab and platinum doublet: A case report.

STK11 loss and SMARCB1 deficiency mutation in a dedifferentiated lung cancer patient present response to neo-adjuvant treatment with pembrolizumab and platinum doublet: A case report.

Journal: Frontiers in oncology
Published: November 03, 2022
Showing 1-12 of 30

Last Updated: 09/26/2026